FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Anand Shah, Richard Pazdur, Shenghui Tang et al.|Clinical Cancer Research|2018

Cited by 115